APR-246 (eprenetapopt)

eprenetapopt · Aprea Therapeutics

Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for APR-246 (eprenetapopt), covering 2022-07-12 to 2022-07-21. Get the full timeline:

Most recent: Clinical Trial Update: p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246 [Phase 2]